Intra-Cellular Therapies reported Q1 2023 financial results, highlighted by a significant increase in total revenues to $95.3 million compared to $35.0 million in the same period of 2022. The growth was primarily driven by net product sales of CAPLYTA, which reached $94.7 million, representing a 173% increase year-over-year. The company also announced positive results from a clinical study evaluating lumateperone in patients with mixed features in major depressive disorder and bipolar depression.